Tags

Type your tag names separated by a space and hit enter

A chart review of patients with early stage mycosis fungoides treated with psoralen plus UVA (PUVA).
J Drugs Dermatol. 2005 May-Jun; 4(3):290-4.JD

Abstract

PUVA has become a common form of treatment for early stage mycosis fungoides (MF). The purpose of this retrospective study was to review the clinical data of 51 MF patients (96% stage IA or IB) treated with PUVA at the Mt. Sinai MF clinic over the past 20 years. We analyzed the efficacy, safety, and remission duration in patients who were treated with a modified PUVA regimen. Forty-four of 51 patients (86%) achieved complete clinical clearing for all stages after initial PUVA therapy. The mean duration of remission with maintenance treatment was more than 27 months (range: 3 weeks to 130 months). The mean duration of disease from start of first PUVA therapy for all patients was 4.8 years (range: 0.7 to 130 months). PUVA for patients with early-stage MF is a safe and effective therapeutic modality with prolonged disease-free remissions, however, PUVA alone was not adequate for more advanced disease.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

15898283

Citation

Soung, Jennifer, et al. "A Chart Review of Patients With Early Stage Mycosis Fungoides Treated With Psoralen Plus UVA (PUVA)." Journal of Drugs in Dermatology : JDD, vol. 4, no. 3, 2005, pp. 290-4.
Soung J, Muigai W, Amin N, et al. A chart review of patients with early stage mycosis fungoides treated with psoralen plus UVA (PUVA). J Drugs Dermatol. 2005;4(3):290-4.
Soung, J., Muigai, W., Amin, N., Stern, D. K., & Lebwohl, M. G. (2005). A chart review of patients with early stage mycosis fungoides treated with psoralen plus UVA (PUVA). Journal of Drugs in Dermatology : JDD, 4(3), 290-4.
Soung J, et al. A Chart Review of Patients With Early Stage Mycosis Fungoides Treated With Psoralen Plus UVA (PUVA). J Drugs Dermatol. 2005 May-Jun;4(3):290-4. PubMed PMID: 15898283.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A chart review of patients with early stage mycosis fungoides treated with psoralen plus UVA (PUVA). AU - Soung,Jennifer, AU - Muigai,Wangui, AU - Amin,Nilam, AU - Stern,Dana K, AU - Lebwohl,Mark G, PY - 2005/5/19/pubmed PY - 2005/7/23/medline PY - 2005/5/19/entrez SP - 290 EP - 4 JF - Journal of drugs in dermatology : JDD JO - J Drugs Dermatol VL - 4 IS - 3 N2 - PUVA has become a common form of treatment for early stage mycosis fungoides (MF). The purpose of this retrospective study was to review the clinical data of 51 MF patients (96% stage IA or IB) treated with PUVA at the Mt. Sinai MF clinic over the past 20 years. We analyzed the efficacy, safety, and remission duration in patients who were treated with a modified PUVA regimen. Forty-four of 51 patients (86%) achieved complete clinical clearing for all stages after initial PUVA therapy. The mean duration of remission with maintenance treatment was more than 27 months (range: 3 weeks to 130 months). The mean duration of disease from start of first PUVA therapy for all patients was 4.8 years (range: 0.7 to 130 months). PUVA for patients with early-stage MF is a safe and effective therapeutic modality with prolonged disease-free remissions, however, PUVA alone was not adequate for more advanced disease. SN - 1545-9616 UR - https://www.unboundmedicine.com/medline/citation/15898283/A_chart_review_of_patients_with_early_stage_mycosis_fungoides_treated_with_psoralen_plus_UVA__PUVA__ L2 - https://www.diseaseinfosearch.org/result/5014 DB - PRIME DP - Unbound Medicine ER -